Starmeša gaismā šodien viesojas mūsu ASV kolēģis Dr. Roberts Ozols.
Te būs viņa stāstījums.
"My personal story mirrors that of many Latvian families who left Latvia during WW II. My father (Robert) was a high school teacher in Riga and my mother (Marina) was a dentist. By a stroke of luck they missed being deported to Siberia after the Russian invasion. I was born in July 1944 behind the front and again, mostly by luck, my mother and I were able to get to Riga and my family left Latvia in October 1944. Th journey to Germany was difficult as were the last months of the war in Frankfurt and then 6 years in displaced persons camp. We came to America in 1950 and while it was not easy at first, we did live the "American Dream". While my father and mother could never resume their professional careers in America, they raised 3 kids and had a comfortable happy life. My wife Jeanne and I will celebrate our 49th wedding anniversary this month and have 3 children and 3 grandchildren--and another one on the way.
I have shortened a biography (below) which has been used in the past.
Robert F. Ozols MD,PhD is Chief Clinical Officer and Professor Emeritus at Fox Chase Cancer Center in Philadelphia. Dr Ozols is an internationally known expert in ovarian cancer and a leader in advancing chemotherapy research. He obtained his professional degrees at the University of Rochester (N.Y.). After his residency in internal medicine at Dartmouth, he obtained his medical oncology training at the National Cancer Institute (NCI). After his fellowship at the NCI, he became a Senior Investigator and Attending Physician in the Medicine Branch NCI. While at the NCI, he received several commendations from the U.S. Public Health Service, was elected to the American Society of Clinical Investigation, and was made Head of The Experimental Therapeutics Section in the Medicine Branch. He came to Fox Chase Center as Chairman of Medicine in 1988 and shortly thereafter became Senior Vice President and was responsible for all clinical and laboratory research in the Division of Medical Science until his retirement in 2010.
Dr Ozols laboratory research has focused on the biology of ovarian cancer and how ovarian cancer cells develop resistance to chemotherapy. He has developed new clinical approaches for the treatment of women with advanced ovarian cancer including regimens which combine carboplatin and paclitaxel which still remain the mainstays of systemic therapy for this disease. He was the Principal Investigator of the NCI's Specialized Programs in Research Excellence (SPORE) in ovarian cancer at Fox Chase from 1999-2008. He has received numerous awards for his laboratory and clinical research, including: The Claude Jacqillat Award in Clinical Oncology (Paris) 2001, The Bristol Myers Squibb Award for Achievement in Cancer Research (2002), The American Society of Clinical Oncology (ASCO) Statesman Award (2008), and the International Gynecologic Cancer Society (IGCS) Award for Excellence in Gynecologic Oncology (2010). ASCO honored him with its Distinguished Achievement Award in 2012.
Dr Ozols is the author of numerous scientific publications, books, and editorials. He has served on numerous editorial boards. He has held senior leadership positions in major scientific and clinical organizations, including: Board of Directors ASCO, American Association of Cancer Institutes, and IGCS as well as Vice President of IGCS. He also served on the Oncology Drug Advisory Committee of the US FDA. For over two decades he was a Principal Investigator in the Gynecologic Oncology Group. He has had numerous advisory positions at the NCI, cancer centers, and cancer care organizations.